The Notch receptors (Notch1-Notch4) are single-transmembranespanning proteins that receive signals from cell-bound ligands encoded by the Jagged (Jag1 and Jag2) and Delta-like (Dll1, Dll3 and Dll4) gene families and thus function by direct cell-to-cell contact or autocrine stimulation 5 . After ligand binding, Notch receptors undergo several proteolytic events that lead to release of the intracellular domains (ICDs) of these receptors. The Notch ICD translocates to the nucleus, where it forms an active transcriptional complex with the DNA-binding protein, C-promoter-binding factor-1 (CBF1; also known as Rbpj (recombination signal-binding protein for immunoglobulin κ J region)), mastermind-like-1 protein and histone acetyltransferases to regulate cell fate and differentiation decisions.
The key downstream genes of Notch signaling are the Hairy/Enhancer of Split (Hes) and Hairy/Enhancer of Split-related (Hrt; also known as Hey) gene families, which, when activated by Notch, reduce expression of downstream transcriptional enhancers such as Mash 6 , MyoD 7 and myocardin 8 , as well as cell cycle regulatory proteins p27 kip1 (ref. 9 ) and p21 waf1/cip1 (ref. 10) . Notch signaling has also been found to directly modulate the expression of platelet-derived growth factor receptor-β (ref. 11) .
Several lines of evidence suggest that Notch3 signaling regulates arterial SMC identity, proliferative capacity and apoptosis. First, Notch3 signaling is crucial in determining the lineage fate of arterial SMCs in the late developing embryo 12 . Second, Notch3 is expressed exclusively on vSMCs in adult mice and rats and expression of this gene has been linked to modulation of nonpulmonary vSMCs Notch3 signaling promotes the development of pulmonary arterial hypertension Xiaodong Li 1 , Xiaoxue Zhang 1 , Robin Leathers 1 , Ayako Makino 2 , Chengqun Huang 1 , Pouria Parsa 1 , Jesus Macias 3 , Jason X-J Yuan 2 
, Stuart W Jamieson 1 & Patricia A Thistlethwaite 1
Notch receptor signaling is implicated in controlling smooth muscle cell proliferation and in maintaining smooth muscle cells in an undifferentiated state. Pulmonary arterial hypertension is characterized by excessive vascular resistance, smooth muscle cell proliferation in small pulmonary arteries, leading to elevation of pulmonary vascular resistance, right ventricular failure and death.
Here we show that human pulmonary hypertension is characterized by overexpression of NOTCH3 in small pulmonary artery smooth muscle cells and that the severity of disease in humans and rodents correlates with the amount of NOTCH3 protein in the lung. We further show that mice with homozygous deletion of Notch3 do not develop pulmonary hypertension in response to hypoxic stimulation and that pulmonary hypertension can be successfully treated in mice by administration of N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT), a -secretase inhibitor that blocks activation of
Notch3 in smooth muscle cells. We show a mechanistic link from NOTCH3 receptor signaling through the Hairy and enhancer of Split-5 (HES-5) protein to smooth muscle cell proliferation and a shift to an undifferentiated smooth muscle cell phenotype. These results suggest that the NOTCH3-HES-5 signaling pathway is crucial for the development of pulmonary arterial hypertension and provide a target pathway for therapeutic intervention. 1 2 9 0 volume 15 | number 11 | november 2009 nature medicine a r t i c l e s into an undifferentiated state 13, 14 . Third, targeted mutagenesis that disrupts Notch3 in mice results in a failure of vSMC maturation in small arteries and arterioles 15 . Fourth, NOTCH3 mutations in humans result in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, a disease characterized by vSMC death in small arteries in the brain, leading to obliteration of the cerebral circulation and brain infarction 16 .
Because PAH is a disease characterized by excessive vSMC proliferation, we tested the hypothesis that there is a direct involvement of NOTCH3 in the development of this disease.
RESULTS

NOTCH3 is a marker for PAH disease severity
To investigate the expression pattern of NOTCH3 in normal and pulmonary hypertensive lungs, we examined lung biopsies from 20 individuals with nonfamilial PAH undergoing lung transplantation compared to biopsies from 20 individuals without pulmonary hypertension, 20 mice with hypoxia-induced pulmonary hypertension compared to 20 control littermates and 20 rats with monocrotaline-induced pulmonary hypertension compared to 20 control littermates ( Fig. 1a,b) . We found elevated levels of NOTCH3 messenger RNA and NOTCH3 ICD protein in human and rodent pulmonary hypertensive lung tissues compared to normotensive lung samples. To characterize whether augmented Notch3 levels were specific to the lung in mice with pulmonary hypertension, we compared organ-specific levels of Notch3 mRNA and Notch3 ICD protein between normal and pulmonary hypertensive mice ( Fig. 1c) . Notch3 mRNA levels were higher in the lung, brain, heart and kidney in mice exposed to 10% oxygen for 6 weeks (pulmonary hypertensive mice) compared to normoxic mice (non-pulmonary hypertensive mice) ( Fig. 1c) . However, we detected minimal amounts of Notch3 ICD protein in most organs, whereas amounts of Notch3 ICD protein in the lung more than tripled in mice with hypoxia-induced pulmonary hypertension ( Fig. 1c) .
Figure 1
Notch3 is a marker for PAH and pulmonary hypertension (PH) disease severity. (a) Northern blot analysis of NOTCH3 relative to 18S RNA from human lungs with idiopathic PAH (three subjects), Notch3 relative to 18s RNA from mice with hypoxia-induced pulmonary hypertension (three mice) and Notch3 relative to 18s RNA from rats with monocrotaline-induced pulmonary hypertension (three rats) compared to control lungs. (b) Top, western blot analysis of NOTCH3 ICD relative to glyceraldehyde 3-phosphate (GAPDH) in the same lung tissue as in a. Bottom, relative expression values obtained by densitometry of NOTCH3 ICD protein normalized to GAPDH (n = 20 for each group). (c) Top, northern blot analysis of Notch3 from organs of mice exposed to hypoxia (H) or normoxia (C) for 6 weeks. Middle and bottom, western blot analysis of Notch3 ICD in the same organs and relative expression values obtained by densitometry of Notch3 protein normalized to Gapdh (n = 4 per group). (d) Top, western blot analysis of NOTCH3 ICD and HES-5 relative to GAPDH in the lungs of subjects with varying severity of PAH and control individuals (left) and western blot analysis of Notch3 ICD and Hes-5 relative to Gapdh from mouse lungs during development of hypoxia-induced pulmonary hypertension or rat lungs during development of monocrotaline-induced pulmonary hypertension, compared to control animals (middle and right). Bottom, relative expression values obtained by densitometry of Notch3 ICD or Hes-5 protein normalized to Gapdh (n = 1 for each PVR listed; n = 20 animals for each time point). PVR, pulmonary vascular resistance. (e) Northern blot analysis of total RNA from the lungs of mice and rats as in d. Data 3 1  2 3  1  2  3  1  2  3  1  2  3  1  2  3 Non a r t i c l e s To test whether NOTCH3 expression correlated with disease progression, we studied humans with varying degrees of PAH, as well as rodents at serial time points during hypoxia-induced or monocrotaline-induced pulmonary hypertension. In human subjects, NOTCH3 ICD levels in the lung correlated directly with the severity of PAH, as measured by pulmonary vascular resistance (PVR) ( Fig. 1d) . For rodents, we performed gene expression analysis ( Fig. 1d,e ) and PAP measurements ( Supplementary Table 1 ) at serial time points after institution of 10% oxygen in mice or monocrotaline injection in rats. There was an increase in Notch3 expression in the lung as a function of time and disease severity for both hypoxiaand monocrotaline-induced pulmonary hypertension in mice and rats, respectively. Hypoxic pulmonary hypertensive mice had higher Notch3 mRNA and Notch3 protein (ICD) expression in their lungs compared to normoxic mice and had PAPs consistent with advanced pulmonary hypertension ( Fig. 1d,e and Supplementary Table 1 ). Rats with monocrotaline-induced pulmonary hypertension had a progressive elevation in steady-state levels of Notch3 mRNA and Notch3 ICD protein in their lungs compared to controls over the course of disease progression ( Fig. 1d,e ). We found no differences in the expression of Notch1, Notch2 or Notch4 in the lungs of normotensive compared to pulmonary hypertensive mice and rats (data not shown). We also found an increase in HES-5 protein expression, a downstream effector target of NOTCH signaling, in human and rodent lungs with PAH or pulmonary hypertension ( Fig. 1d) . High levels of HES-5 in lung tissue correlated with worsening disease severity ( Fig. 1d and Supplementary Table 1 ). In contrast to Hes5, we found no differences in the expression of the other known Notch3 target genes, Hes1, Hes7, Hrt1 (also known as Hey1), Hrt2 (also known as Hey2) and Hrt3 (also known as Heyl), in the lungs of normotensive compared to pulmonary hypertensive humans and rodents ( Supplementary Fig. 1 ). Our results indicate that levels of NOTCH3 and HES-5 correlate with the severity of PAH in humans and pulmonary hypertension in two murine models of disease.
NOTCH3 and HES-5 expression are confined to vSMCs in the lung
Immunofluorescent staining of human and mouse lung showed that NOTCH3 and HES-5 expression was confined to vSMCs in small pulmonary arteries measuring <1,500 µm in diameter ( Fig. 2a,b) . NOTCH3 staining was localized in the media of small pulmonary arteries, with sporadic staining in the neointima ( Supplementary  Fig. 2 ). We did not detect NOTCH3 or HES-5 staining in vSMCs from pulmonary veins or venules (data not shown). We observed higher levels of NOTCH3 and HES-staining in vSMCs from pulmonary hypertensive lung tissues compared to normotensive age-and sex-matched control lung tissue in both humans and mice ( Fig. 2a,b) .
To characterize differences between PAH and non-PAH vSMCs, we subcultured small pulmonary artery SMCs (sPASMCs) from humans with and without PAH. Analysis of subcultured sPASMCs (isolated from 500-1,500-µm diameter vessels) from individuals with PAH showed that steady-state levels of NOTCH3 mRNA and NOTCH3 protein as well as HES5 mRNA and HES-5 protein were increased in these cells compared to sPASMCs subcultured from humans without PAH ( Fig. 2c,d) .
Notch3 increases proliferation of sPASMCs through HES-5
As vSMC proliferation is one of the underlying mechanisms of vascular remodeling in PAH, we investigated whether increased levels of Notch3 ICD protein affected proliferation of human sPASMCs. Subcultured sPASMCs infected with the Notch3 ICD adenovirus (amino acid sequence for Notch3 ICD in Supplementary Methods) showed increases in Notch3 ICD protein and HES-5 protein expression compared with lacZ-transduced sPASMCs (Fig. 3a) . Analysis of the effects of constitutive, high-level Notch3 expression a r t i c l e s in sPASMCs revealed a significantly increased growth rate at preconfluence and increased proliferation, as determined by 3 [H]leucine incorporation ( Fig. 3b) .
To test whether the effect of Notch3 ICD on human sPASMC proliferation was dependent on Notch signaling through HES-5, we used HES5-specific small interfering RNA (HES5 siRNA) to lower HES5 expression. Transfection of HES5 siRNA into vSMCs constitutively expressing Notch3 ICD significantly decreased HES5 expression ( Fig. 3c ) and 3 [H]leucine incorporation ( Fig. 3d) ; both were unaffected in vSMCs constitutively expressing Notch3 ICD transfected with a control (scrambled) oligonucleotide ( Fig. 3c,d) . These results suggest that an upregulated NOTCH3-HES-5 signaling pathway has a major role in the proliferation of human sPASMCs.
Proliferation of PAH sPASMCs is dependent on NOTCH3-HES-5
We next compared growth rates and gene expression patterns of sPASMCs from ten human subjects with idiopathic PAH to ten human subjects without PAH. sPASMCs from subjects with PAH had lower levels of several contractile SMC markers (SMTN (encoding smoothelin) and MYH11 (encoding myosin heavy chain)) compared to sPASMCs from individuals without PAH. In contrast, expression of the genes encoding the contractile proteins α-smooth muscle-actin (ACTA2) and calponin (CNN1) was slightly increased in PAH vSMCs compared to normotensive vSMCs (Fig. 4a) . sPASMCs from PAH lungs showed significantly shorter doubling times and higher rates of 3 [H]leucine incorporation compared to sPASMCs from non-PAH lungs (Fig. 4b) .
To test whether HES-5 contributed to the enhanced in vitro proliferative rate of sPASMCs from human subjects with PAH versus subjects without PAH, we used HES5 siRNA to knock down expression of this gene product (Fig. 4c) . Inhibition of HES5 expression markedly attenuated PAH vSMC proliferation and 3 [H] leucine incorporation, suggesting that NOTCH signaling through HES-5 may have a role in the development of pulmonary medial hypertrophy ( Fig. 4d) . siRNA-mediated knockdown of HES5 in PAH sPASMCs also resulted in increased expression of the vSMC contractile markers MYH11 and SMTN over that seen in untreated or scrambled siRNA-treated PAH sPASMCs ( Fig. 4a,e ). These observations suggest that the enhanced NOTCH signaling through HES-5 seen in PAH vSMCs may contribute to the ability of these cells to proliferate and lose expression of markers of contractile vSMCs.
Notch3 −/− mice do not develop pulmonary hypertension
To test whether Notch3 signaling is required for development of pulmonary hypertension, we studied Notch3-knockout mice (with homozygous deletion of Notch3, lacking 2.5 kb of the genomic sequence encoding epidermal growth factor-like repeats 8-12 in the extracellular domain 17 ) for development of hypoxia-induced pulmonary hypertension. Notch3 −/− mice had minimal expression of Hes-5 in the lung in both hypoxic (10% oxygen) and normoxic conditions (Fig. 5a) . In contrast, wild-type lungs showed high amounts of Notch3 ICD and Hes-5 protein in mice that were subjected to hypoxia (Fig. 5a) .
Notch3 −/− mice did not develop elevated right ventricular systolic pressures (RVSP) over a 6-week period of hypoxia ( Fig. 5b) .
In contrast, wild-type and Notch3 +/− littermates manifested progressively elevated RVSP, with a mean increase from 18.6 mm Hg to 32.5 mm Hg (wild-type) and from 18.8 mm Hg to 34.6 mm Hg (heterozygotes) over 6 weeks of hypoxia. Notch3 +/+ and Notch3 +/− mice developed abnormal small pulmonary artery muscularization and luminal narrowing consistent with advanced pulmonary hypertension, whereas Notch3 −/− mice had normal-appearing small arteries without excessive muscular thickening (Fig. 5c) . Expression a r t i c l e s of proliferating cell nuclear antigen (PCNA) was lower in small pulmonary arteries in Notch3 −/− compared to wild-type mice at 4 and 6 weeks in hypoxia ( Fig. 5c,d) . We quantified changes in wall thickness and morphology for small pulmonary arteries in the range of 15-250-µm diameter for Notch3 −/− , Notch3 +/− and Notch3 +/+ mice ( Supplementary Table 2a ). Pulmonary vessel medial thickening during hypoxia correlated directly with cellular proliferation, as measured by the number of cells positively stained for PCNA in wild-type mice (Fig. 5c,d and Supplementary Table 2a ). Notch3 −/− mice had an absence of medial thickening of small pulmonary arteries and arterioles and had minimally detectable PCNA staining in lung vSMCs (Fig. 5c,d) . Vessel/alveoli ratios were not significantly different between Notch3 −/− and Notch3 +/+ or Notch3 +/− mice ( Supplementary Table 2a ). Notch3 −/− mice, maintained in hypoxic conditions for 6 weeks, had normal pulmonary angiograms with diffuse vascular blush, whereas wild-type littermates had angiograms showing severe small-vessel pruning similar to that seen in human PAH (Fig. 5e) . We confirmed the absence of pulmonary hypertension in Notch3 −/− mice by cardiac measurements of chamber weight. Right ventricular weight, compared to that of the left ventricle and septum, was used as an index of right ventricular hypertrophy. This ratio was minimally changed over the course of hypoxia in Notch3 −/− mice, whereas it significantly increased over the course of hypoxia in Notch3 +/+ and Notch3 +/− mice (Fig. 5f) .
To examine whether the absence of pulmonary hypertension in Notch3 −/− mice could be attributed to inhibition of pulmonary vasoconstriction, alterations in pulmonary vessel myogenic tone or changes in pulmonary vasoreactivity to pulmonary blood flow, we did four sets of experiments. First, we compared agonist-mediated vasoconstriction of isolated intrapulmonary small arteries from Notch3 −/− mice and wild-type littermates. The active tension induced by high K + and prostaglandin F 2α treatment of pulmonary arterial rings was not different between rings from Notch3 −/− and Notch3 +/+ mice (Supplementary Fig. 3a) . Second, to assess the relationship between myogenic tone and pulmonary blood flow in Notch3 +/+ and Notch3 −/− mice, we studied pressure-flow relationships in an isolated ventilated, perfused lung system 18 . We found that in both Notch3 +/+ and Notch3 −/− mouse lungs, incremental increases in pulmonary blood flow caused similar augmentation of PAP (Supplementary Fig. 3b ). Third, we measured pulmonary and systemic hemodynamic responses to an acute vasodilator, intravenous epoprostenol, in Notch3 +/+ and Notch3 −/− normoxic and chronically hypoxic mice. Under normoxic conditions, Notch3 +/+ and Notch3 −/− mice had no difference in pulmonary vasoreactivity to vasodilator infusion and had similar baseline measurements for PAP and total PVR (Supplementary Fig. 4) . Compared to wild-type normoxic mice, chronically hypoxic Notch3 +/+ mice had less change in mean PAP and total PVR in response to vasodilator challenge (Supplementary Fig. 4 ), suggesting that the pulmonary hypertension of these mice is, in part, 'fixed', due to HES5 mRNA (arbitrary units) 3 [H]leucine incorpration (fold increase) 3 [H]leucine incorpration (fold increase) (Supplementary Fig. 4) . Fourth, we performed electron microscopy to analyze vSMCs within the media of small pulmonary arteries of Notch3 +/+ and Notch3 −/− mice. Structural abnormalities in vSMCs from tail and cerebral arteries of Notch3 −/− mice have been speculated to account for altered flow-induced vasoreactivity in these vessels 19 . However, we found no differences in vSMC morphology in small pulmonary arteries between Notch3 +/+ and Notch3 −/− mice (Supplementary Fig. 5 ), suggesting that Notch3 has differing roles in vasomotor tone in the systemic and pulmonary circulations. Collectively, our results show that Notch3 signaling is mainly involved in pulmonary vascular remodeling, rather than in affecting pulmonary vasoreactivity.
Notch3 inhibition reverses pulmonary hypertension in mice
The γ-secretase inhibitor DAPT has been shown to block the cleavage of Notch proteins to ICD peptides both in vitro and in vivo 20 .
We tested our hypothesis that Notch3 signaling is required for the development of pulmonary hypertension and that pharmacological blockade of Notch3 cleavage would effectively treat and reverse this disease. We first performed dose-response experiments to determine the half-maximal effective dose of DAPT for inhibition of Notch3 cleavage in the lung. We induced hypoxic pulmonary hypertension in mice (begun on day 1) and then treated them with a daily subcutaneous dose of 10 mg per kg body weight DAPT from day 15 to day 42 while they were in 10% oxygen. Although gastrointestinal side effects have been reported with γ-secretase inhibitor administration to mice 21 , we did not observe any overt side effects with DAPT administration at this dose. We assessed inhibition of Notch3 cleavage in lung tissue by western blotting (Fig. 6a) and immunohistochemistry (Fig. 6b) at biweekly intervals over the course of DAPT administration. We found that levels of Notch3 ICD and Hes5 were decreased in the lungs of DAPT-treated mice compared to placebo-treated mice (Fig. 6a,b) . At time points after institution of hypoxia, before and after DAPT treatment, we examined RVSP and systemic arterial blood pressure (SBP) of DAPT-treated and saline-treated controls (Fig. 6c) . Administration of DAPT reversed hypoxia-induced pulmonary hypertension (Fig. 6c,d) . Mice receiving this compound had significant reductions in RVSPs relative to SBPs (P < 0.01), whereas control mice developed pulmonary hypertension with elevated RVSPs (Fig. 6c) . Whereas sham-treated mice developed progressive medial thickening of small pulmonary arteries and arterioles, consistent with the usual pattern of pulmonary hypertension development in hypoxic animals, we found that mice treated with DAPT had normal-appearing pulmonary vessels with rarely detected medial thickening or vessel occlusion, as assessed by histology and semiquantitative morphometric analysis of distal pulmonary vessels ( Fig. 6d and Supplementary  Table 2b ). Using staining for PCNA, we observed few proliferating vSMCs in the walls of small pulmonary arteries of DAPT-treated mice compared to sham-treated controls (Fig. 6d) . Furthermore, we found that treatment with DAPT increased the number of apoptotic cells in the remodeled small pulmonary arteries in chronically hypoxic mice (Fig. 6e) . These results indicate that the therapeutic effect of DAPT on hypoxia-induced pulmonary hypertension involves both antiproliferative and proapoptotic effects on sPASMCs. Angiograms performed in chronically hypoxic, DAPT-treated mice showed diffuse vascular blush consistent with a patent distal pulmonary vascular tree, whereas angiograms performed in control mice showed blunting of the pulmonary vasculature with absence of peripheral artery filling (Fig. 6f) . Vessel/alveoli ratios were not significantly different between hypoxic DAPT-treated and Table 2b) , suggesting that the vascular pruning seen with angiography in control mice was due to vessel stenosis and occlusion rather than vessel loss. Mice treated with DAPT had regression of right ventricular hypertrophy, further indicating that they were effectively treated for pulmonary hypertension (Fig. 6g) .
DISCUSSION
Biochemical, genetic and clinical evidence indicates that SMC proliferation in small pulmonary vessels is an essential part of the pathogenesis of pulmonary hypertension. This study identifies Notch3 as a crucial mediator of sPASMC proliferation and a crucial mediator for the development of rodent pulmonary hypertension and, possibly, human PAH. Our goal has been to understand the molecular basis by which normal pulmonary vessels develop smooth muscle hyperplasia and medial thickening, which eventually occlude the distal pulmonary arterial tree and cause clinical manifestations of PAH. As a result of the work reported, we have four major conclusions. First, we showed that human PAH vasculopathy is characterized by high steady-state levels of NOTCH3 and its downstream effector HES-5 in SMCs lining small pulmonary arteries and arterioles. We further found that the amount of NOTCH3 protein in the lung correlates with PAH and pulmonary hypertension disease severity in humans and rodents, respectively. These results establish a link between NOTCH3 signaling and the magnitude of pulmonary hypertension. Second, we showed that constitutive Notch3 ICD expression induces sPASMC proliferation. This finding, coupled with the observation that NOTCH3 mRNA and NOTCH3 protein are overexpressed in the lungs of humans with PAH, support a potentially crucial role of NOTCH signaling in mediating the vSMC proliferation seen in this disease. We found that siRNA inhibition of HES5 expression caused a decrease in sPASMC proliferation and a shift in gene expression in vSMCs toward a more differentiated phenotype. These results establish a link between NOTCH3 signaling Week 6
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Week 4 a r t i c l e s and the regulation of HES-5 effector expression in the context of vSMC proliferation. Third, we show that Notch3 is requisite for the development of pulmonary hypertension in mice. Notch3 −/− mice were resistant to the development of pulmonary hypertension and were unable to generate a medial hypertrophic response to hypoxia, indicating that Notch3-mediated proliferative and possibly antiapoptotic effects on sPASMCs are required for the development of pulmonary vascular medial hypertrophy. Fourth, we found that pulmonary hypertension in mice can be effectively treated by blocking Notch3 signaling. Collectively, these results suggest that NOTCH3 signaling is required for the clinical and pathological development of PAH and pulmonary hypertension.
In the early stages of human PAH, the disease has two components: pulmonary vasoconstriction and vascular remodeling. As the disease progresses, the capacity of the pulmonary vascular bed to dilate and recruit unused vasculature is lost [22] [23] [24] [25] . Recently, it has been suggested that Notch3 deficiency causes a reduction in pressure-induced myogenic tone and enhanced flow-mediated dilation in tail arteries of rats, associated with a reduction in RhoA activity 19 . Chronically hypoxic rats have been found to have increased myogenic tone in small pulmonary arteries through a RhoA kinase-dependent myofilament Ca 2+ sensitization 26 . These results raise the possibility that Notch3 may modulate not only pulmonary vessel wall remodeling but also pulmonary vascular tone and dilation. However, when we examined the effects of Notch3 deficiency on the pulmonary circulation, we saw little difference between Notch3 +/+ and Notch3 −/− mice with regard to flow-induced changes in pulmonary arterial pressure or their responses to vasoconstrictor drugs or pulmonary vasodilators. These results suggest that Notch3 may have different functions in the pulmonary and systemic circulations.
Clues as to why NOTCH3 may have a role in PAH come from studies of Notch function in modulating vSMC phenotype, its involvement in cross talk with bone morphogenetic protein (BMP) signaling and its role in the setting of hypoxia. Notch signaling through Hes and Hrt proteins has been associated with lack of cell cycle arrest in aortic SMCs 9,13 , has been reported to repress myocardin-induced differentiation of myofibroblasts 8 and has been found to regulate SMC proliferation in the setting of neointimal injury in Hrt2-deficient and Notch1 +/− mice 27, 28 . Although these studies suggest a role of Notch signaling in SMC proliferation and homeostasis, to our knowledge no such studies have been done to test the role of Notch signaling in sPASMCs. As the biologic response to Notch receptor activation varies with cell type and organ context 29 , it is difficult to extend findings from various vascular beds or immortialized cell lines to the behavior of SMCs from the distal pulmonary vascular tree.
NOTCH3 may affect sPASMC remodeling in PAH through crosstalk with the BMP receptor (BMPR) signaling pathway. BMPR2 mutations have been found to be associated with the development of familial human PAH 30 . However, 40% of individuals with familial PAH do not harbor mutations in BMPR2, and most nonfamilial cases lack association with BMPR2 mutation 31 . This suggests that alternate or convergent pathways to BMPR signaling may contribute to this disease. Recently, integration between Notch and BMP signaling has been found in several organs and cell types. Activation of BMP signaling has been found to lead to enhanced transcription of the Notch target gene Herp2 (Hrt1), through binding of the intracellular BMP-mediated transcription factor, Smad-1, to Notch ICD [32] [33] [34] . Notably, Hrt1 was found to efficiently bind to and induce degradation of inhibitor of DNA binding-1 (Id-1), a downstream effector of BMP signaling 35 . A protein-protein interaction between Id-2 (downstream of BMP signaling) and Hes-1 (downstream of Notch signaling) in the chicken hindbrain has been shown to be a key regulator of gene expression in neurogenesis 33 . These feedback loops provide evidence that Notch signaling, in certain organs, may modulate other signaling pathways downstream of BMPR activation. A second line of evidence suggesting that NOTCH signaling may be essential to the development of PAH is its role in hypoxia, an environmental inducer of this disease. Hypoxia promotes the undifferentiated cell state in various stem cell and precursor populations 36 , and this effect of hypoxia requires functional Notch signaling 37 . In a mechanism similar to the crosstalk between BMP and Notch signaling, hypoxia-inducible factor-1α, an intracellular mediator of oxygen sensing, has been found to bind Notch ICD and act as a coenhancer to stimulate transcription of Notch-responsive genes under hypoxic conditions. Thus, NOTCH ICD is at the convergence point of two signaling mechanisms: hypoxia-inducible factor-1α signaling and BMP signaling, both of which have been implicated in the development of PAH.
In summary, we find that high steady-state levels of NOTCH3 are associated with the development of PAH in humans and that Notch3 expression is required for the development of pulmonary hypertension in two experimental models of this disease. Our work shows that constitutive Notch3 signaling induces a proliferative phenotype in pulmonary vSMCs and that pulmonary hypertensive vascular pathology in vivo can be prevented by treatment with a drug that blocks Notch signaling. It is possible that other Notch receptors may also have a role in the development of pulmonary hypertension, and more specific inhibitors of NOTCH3 signaling will need to be tested in the treatment of this disease. Our results suggest that inhibition of the expression or effect of NOTCH3 signaling in the adult pulmonary vasculature may be a useful strategy to prevent and treat PAH in humans.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
